Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401585 | 0.90 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL1270141 | 0.90 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL270318 | 0.90 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL270319 | 0.90 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL29907906 | 0.90 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL27138772 | 0.89 | CTSS (0.54) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL31494606 | 0.89 | CTSS (0.54) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL27149947 | 0.89 | CTSS (0.54) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL5041377 | 0.89 | CTSS (0.53) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL7094300 | 0.89 | CTSS (0.53) | CTSSCTSKPTPN1ACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117623973-A | Resolution method of N-acetyl-4-trifluoromethyl phenylalanine and application thereof | 瑞博(杭州)医药科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021194828-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| CN-1623980-A | Method for preparing optical pure N-tertiary butyl oxycarbonyl-beta-difluorine phenylalanine | YAOMINGKANGDE NEW PHARMACEUTIC (CN) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CTSS 138/4885CTSK 149/4885PTPN1 2222/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CTSS 138/4885CTSK 149/4885PTPN1 2222/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | CTSS 138/4885CTSK 149/4885PTPN1 2222/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | CTSS 138/4885CTSK 149/4885PTPN1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.